Literature DB >> 19060728

The effect of propranolol on posttraumatic stress disorder in burned service members.

Laura L McGhee1, Christopher V Maani, Thomas H Garza, Peter A Desocio, Kathryn M Gaylord, Ian H Black.   

Abstract

Posttraumatic stress disorder (PTSD) is reported to affect almost one third of the civilian burn patient population. Predisposing factors for PTSD include experiencing a traumatic event. Of Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) soldiers returning home after deployment without injury, 17% reported cognitive symptoms of PTSD. The authors recent study of soldiers burned in OIF/OEF showed a PTSD prevalence of approximately 30%, which is similar to civilian studies. Burns are characterized by hypermetabolism and increased catecholamine levels. beta-Adrenergic receptor blocking agents, like propranolol, decrease catecholamine levels. Propranolol may reduce consolidation of memory and a prophylaxis for PTSD. This retrospective study examines the relationship between PTSD prevalence and propranolol administration. After institutional review board approval, propranolol received, number of surgeries, anesthetic/analgesic regimen, TBSA burned, and injury severity score were collected from patients charts. The military burn center received 603 soldiers injured in OIF/OEF, of which 226 completed the PTSD Checklist-Military. Thirty-one soldiers received propranolol and 34 matched soldiers did not. In propranolol patients, the prevalence of PTSD was 32.3% vs 26.5% in those not receiving propranolol (P = .785). These data suggest propranolol does not decrease PTSD development in burned soldiers. The prevalence of PTSD in patients receiving propranolol is the same as those not receiving propranolol. More research is needed to determine the relationship between PTSD and propranolol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19060728     DOI: 10.1097/BCR.0b013e3181921f51

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  27 in total

Review 1.  Transcriptional Regulation Involved in Fear Memory Reconsolidation.

Authors:  Xu Wang; Min Li; Haitao Zhu; Yongju Yu; Yuanyuan Xu; Wenmo Zhang; Chen Bian
Journal:  J Mol Neurosci       Date:  2018-05-23       Impact factor: 3.444

Review 2.  [Targeted prevention of posttraumatic stress disorder].

Authors:  J Hellmann; I Heuser; G Kronenberg
Journal:  Nervenarzt       Date:  2011-07       Impact factor: 1.214

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 4.  A Review of Psychopharmacological Interventions Post-Disaster to Prevent Psychiatric Sequelae.

Authors:  Badari Birur; Suresh Bada Math; Rachel E Fargason
Journal:  Psychopharmacol Bull       Date:  2017-01-26

Review 5.  Does neuroimaging research examining the pathophysiology of posttraumatic stress disorder require medication-free patients?

Authors:  Ruth A Lanius; Chris R Brewin; J Douglas Bremner; Judith K Daniels; Matthew J Friedman; Israel Liberzon; Alexander McFarlane; Paula P Schnurr; Lisa Shin; Murray Stein; Eric Vermetten
Journal:  J Psychiatry Neurosci       Date:  2010-03       Impact factor: 6.186

Review 6.  Implications of memory modulation for post-traumatic stress and fear disorders.

Authors:  Ryan G Parsons; Kerry J Ressler
Journal:  Nat Neurosci       Date:  2013-01-28       Impact factor: 24.884

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

8.  Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury.

Authors:  Danielle C Orrey; Omar I Halawa; Andrey V Bortsov; Jeffrey W Shupp; Samuel W Jones; Linwood R Haith; Janelle M Hoskins; Marion H Jordan; Shrikant I Bangdiwala; Brandon R Roane; Timothy F Platts-Mills; James H Holmes; James Hwang; Bruce A Cairns; Samuel A McLean
Journal:  Clin J Pain       Date:  2015-01       Impact factor: 3.442

Review 9.  Burns: an update on current pharmacotherapy.

Authors:  Yesenia Rojas; Celeste C Finnerty; Ravi S Radhakrishnan; David N Herndon
Journal:  Expert Opin Pharmacother       Date:  2012-11-02       Impact factor: 3.889

Review 10.  Revisiting propranolol and PTSD: Memory erasure or extinction enhancement?

Authors:  Thomas F Giustino; Paul J Fitzgerald; Stephen Maren
Journal:  Neurobiol Learn Mem       Date:  2016-01-22       Impact factor: 2.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.